Figure 1.

Reconstitution of splenic immune subsets after TBI. Mice receive 1×10⁵ B16 tumor cells on day 0 followed by 600 rad TBI on day 3. Spleen cells from (A) wild type and (B) B16 tumor bearing mice were analyzed for CD4⁺, CD8⁺, CD11b⁺Gr-1⁺ MDSC and CD4⁺CD25⁺foxp3⁺ Tregs on days 3, 7, 10, 14 and 21. Data represents the percent of normal compared to splenocytes from mice not treated with TBI. Data are representative of three independent experiments (n=4).